Intranasal Coronavirus SARS-CoV-2 Immunization with Lipid Adjuvants Provides Systemic and Mucosal Immune Response against SARS-CoV-2 S1 Spike and Nucleocapsid Protein

被引:9
作者
Sengupta, Anirban [1 ]
Azharuddin, Mohammad [1 ]
Cardona, Maria E. [2 ]
Devito, Claudia [1 ]
von Castelmur, Eleanore [2 ]
Wehlin, Anna [2 ]
Pietras, Zuzanna [2 ]
Sunnerhagen, Maria [2 ]
Selegard, Robert [2 ]
Aili, Daniel [2 ]
Alamer, Ali [3 ]
Hinkula, Jorma [1 ]
Al-Otaibi, Noha [3 ]
机构
[1] Linkoping Univ, Dept Biomed & Clin Sci, S-58185 Linkoping, Sweden
[2] Linkoping Univ, Dept Phys Chem & Biol, Div Biophys & Bioengn, Lab Mol Mat,IFM, S-58183 Linkoping, Sweden
[3] King Abdulaziz City Sci & Technol KACST, Riyadh 11442, Saudi Arabia
关键词
pandemic; COVID-19; immunity; vaccine; formula; antigen; adjuvants; NASAL; MICE; IMMUNOGENICITY; PARTICLES; DELIVERY; CHITOSAN;
D O I
10.3390/vaccines10040504
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
In this preclinical two-dose mucosal immunization study, using a combination of S1 spike and nucleocapsid proteins with cationic (N3)/or anionic (L3) lipids were investigated using an intranasal delivery route. The study showed that nasal administration of low amounts of antigens/adjuvants induced a primary and secondary immune response in systemic IgG, mIL-5, and IFN-gamma secreting T lymphocytes, as well as humoral IgA in nasal and intestinal mucosal compartments. It is believed that recipients will benefit from receiving a combination of viral antigens in promoting a border immune response against present and evolving contagious viruses. Lipid adjuvants demonstrated an enhanced response in the vaccine effect. This was seen in the significant immunogenicity effect when using the cationic lipid N3. Unlike L3, which showed a recognizable effect when administrated at a slightly higher concentration. Moreover, the findings of the study proved the efficiency of an intranasally mucosal immunization strategy, which can be less painful and more effective in enhancing the respiratory tract immunity against respiratory infectious diseases.
引用
收藏
页数:12
相关论文
共 44 条
[1]   Chitosan and trimethyl chitosan chloride (TMC) as adjuvants for inducing immune responses to ovalbumin in mice following nasal administration [J].
Boonyo, Worawan ;
Junginger, Hans E. ;
Waranuch, Neti ;
Polnok, Assadang ;
Pitaksuteepong, Tasana .
JOURNAL OF CONTROLLED RELEASE, 2007, 121 (03) :168-175
[2]   Competitive SARS-CoV-2 Serology Reveals Most Antibodies Targeting the Spike Receptor-Binding Domain Compete for ACE2 Binding [J].
Byrnes, James R. ;
Zhou, Xin X. ;
Lui, Irene ;
Elledge, Susanna K. ;
Glasgow, Jeff E. ;
Lim, Shion A. ;
Loudermilk, Rita P. ;
Chiu, Charles Y. ;
Wang, Taia T. ;
Wilson, Michael R. ;
Leung, Kevin K. ;
Wells, James A. .
MSPHERE, 2020, 5 (05)
[3]   Age-associated SARS-CoV-2 breakthrough infection and changes in immune response in a mouse model [J].
Chen, Yanxia ;
Li, Can ;
Liu, Feifei ;
Ye, Zhanhong ;
Song, Wenchen ;
Lee, Andrew C. Y. ;
Shuai, Huiping ;
Lu, Lu ;
To, Kelvin Kai-Wang ;
Chan, Jasper Fuk-Woo ;
Zhang, Anna Jinxia ;
Chu, Hin ;
Yuen, Kwok-Yung .
EMERGING MICROBES & INFECTIONS, 2022, 11 (01) :368-383
[4]   The SARS-CoV-2 nucleocapsid protein is dynamic, disordered, and phase separates with RNA [J].
Cubuk, Jasmine ;
Alston, Jhullian J. ;
Incicco, J. Jeremias ;
Singh, Sukrit ;
Stuchell-Brereton, Melissa D. ;
Ward, Michael D. ;
Zimmerman, Maxwell I. ;
Vithani, Neha ;
Griffith, Daniel ;
Wagoner, Jason A. ;
Bowman, Gregory R. ;
Hall, Kathleen B. ;
Soranno, Andrea ;
Holehouse, Alex S. .
NATURE COMMUNICATIONS, 2021, 12 (01)
[5]   Combining spike- and nucleocapsid-based vaccines improves distal control of SARS-CoV-2 [J].
Dangi, Tanushree ;
Class, Jacob ;
Palacio, Nicole ;
Richner, Justin M. ;
MacMaster, Pablo Penaloza .
CELL REPORTS, 2021, 36 (10)
[6]   Th1 skewed immune response of whole virion inactivated SARS CoV 2 vaccine and its safety evaluation [J].
Ganneru, Brunda ;
Jogdand, Harsh ;
Daram, Vijaya Kumar ;
Das, Dipankar ;
Molugu, Narasimha Reddy ;
Prasad, Sai D. ;
Kannappa, Srinivas, V ;
Ella, Krishna M. ;
Ravikrishnan, Rajaram ;
Awasthi, Amit ;
Jose, Jomy ;
Rao, Panduranga ;
Kumar, Deepak ;
Ella, Raches ;
Abraham, Priya ;
Yadav, Pragya D. ;
Sapkal, Gajanan N. ;
Shete-Aich, Anita ;
Desphande, Gururaj ;
Mohandas, Sreelekshmy ;
Basu, Atanu ;
Gupta, Nivedita ;
Vadrevu, Krishna Mohan .
ISCIENCE, 2021, 24 (04)
[7]   Development of an inactivated vaccine candidate for SARS-CoV-2 [J].
Gao, Qiang ;
Bao, Linlin ;
Mao, Haiyan ;
Wang, Lin ;
Xu, Kangwei ;
Yang, Minnan ;
Li, Yajing ;
Zhu, Ling ;
Wang, Nan ;
Lv, Zhe ;
Gao, Hong ;
Ge, Xiaoqin ;
Kan, Biao ;
Hu, Yaling ;
Liu, Jiangning ;
Cai, Fang ;
Jiang, Deyu ;
Yin, Yanhui ;
Qin, Chengfeng ;
Li, Jing ;
Gong, Xuejie ;
Lou, Xiuyu ;
Shi, Wen ;
Wu, Dongdong ;
Zhang, Hengming ;
Zhu, Lang ;
Deng, Wei ;
Li, Yurong ;
Lu, Jinxing ;
Li, Changgui ;
Wang, Xiangxi ;
Yin, Weidong ;
Zhang, Yanjun ;
Qin, Chuan .
SCIENCE, 2020, 369 (6499) :77-+
[8]   On the mechanism whereby cationic lipids promote intracellular delivery of polynucleic acids [J].
Hafez, IM ;
Maurer, N ;
Cullis, PR .
GENE THERAPY, 2001, 8 (15) :1188-1196
[9]   Immunization with heat-killed Mycobacterium bovis bacille Calmette-Guerin (BCG) in Eurocine™ L3 adjuvant protects against tuberculosis [J].
Haile, M ;
Schröder, U ;
Hamasur, B ;
Pawlowski, A ;
Jaxmar, T ;
Källenius, G ;
Svenson, SB .
VACCINE, 2004, 22 (11-12) :1498-1508
[10]   Serological and molecular findings during SARS-CoV-2 infection: the first case study in Finland, January to February 2020 [J].
Haveri, Anu ;
Smura, Teemu ;
Kuivanen, Suvi ;
Osterlund, Pamela ;
Hepojoki, Jussi ;
Ikonen, Niina ;
Pitkapaasi, Marjaana ;
Blomqvist, Soile ;
Ronkko, Esa ;
Kantele, Anu ;
Strandin, Tomas ;
Kallio-Kokko, Hannimari ;
Mannonen, Laura ;
Lappalainen, Maija ;
Broas, Markku ;
Jiang, Miao ;
Siira, Lotta ;
Salminen, Mika ;
Puumalainen, Taneli ;
Sane, Jussi ;
Melin, Merit ;
Vapalahti, Olli ;
Savolainen-Kopra, Carita .
EUROSURVEILLANCE, 2020, 25 (11) :16-21